The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 02, 2016
Filed:
Mar. 11, 2014
Pharmabcine Inc., Daejeon, KR;
Jin-San Yoo, Daejeon, KR;
Weon-Sup Lee, Daejeon, KR;
Sang-Ryeol Shim, Daejeon, KR;
Mi-Hee Park, Daejeon, KR;
Jeong-Eun Kang, Daejeon, KR;
Do-Yun Kim, Seoul, KR;
Joon-Chul Lee, Incheon, KR;
Dong-Heon Lee, Daejeon, KR;
Too-Hyon Cho, Incheon, KR;
Sam-Sook Sul, Incheon, KR;
Young-Guen Kwon, Seoul, KR;
Bo-Jeong Pyun, Seoul, KR;
Kwi-Hwa Kim, Daejeon, KR;
Chae-Ok Yun, Seoul, KR;
Nahm-Ju Kim, Daejeon, KR;
Jae-Won Jeon, Daejeon, KR;
Dong-Sup Lee, Seoul, KR;
Young-Woo Park, Daejeon, KR;
Geun-Bae Rha, Cheongju-si, KR;
Hyun-Sook Jang, Daejeon, KR;
Hyeon-Mi Yoo, Daejeon, KR;
Sung-Woo Kim, Daejeon, KR;
Semi Kim, Daejeon, KR;
Sang-Seok Koh, Daejeon, KR;
PHARMABCINE INC., Daejeon, KR;
Abstract
The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.